Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Infliximab Induction in Pediatric Crohn's Disease
NCT05552287Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in Crohn's disease, sponsored by Erasmus MC. Started Aug 2023; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05552287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552287.